Riyaz Shah, FRCP, PhD, Maidstone and Tunbridge Wells NHS Trust, Kent, UK, reviews some of the highlights from studies presented at ASCO, including the CITYSCAPE and CheckMate 9LA trials. The CITYSCAPE study (NCT03563716) evaluated tiragolumab plus atezolizumab versus placebo plus atezo as first-line t6reatment in patients with PD-L1-selected non-small cell lung cancer (NSCLC) and showed clinically meaningful improvements in overall response rates and progression free survival in the intent to treat population. The CheckMate 9LA study (NCT03215706) compared nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles chemotherapy as first-line treatment for stage IV/recurrent NSCLC. The study met it’s primary endpoint: a statistically significant improvement in overall surival with nivolumab + ipilimumab + chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).